Cyclophosphamide for multiple sclerosis (Q24243160)

4

0 references

Bianca Weinstock-Guttman

5

object named as

Bianca Weinstock-Guttman

0 references

author name string

Clara Milanese

2

0 references

Nerina Mascoli

Cochrane Database of Systematic Reviews

3

0 references

publication date

24 January 2007

0 references

published in

0 references

cites work

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

Cyclophosphamide and plasma exchange in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

Cumulative experience with high-dose intravenous cyclophosphamide and ACTH therapy in chronic progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

Cyclophosphamide in relapsing remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

Treatment of progressive multiple sclerosis with monthly pulsed cyclophosphamide-methylprednisolone: predictive factors of treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

Cyclophosphamide in exacerbations of multiple sclerosis. Therapeutic trial and a strategy for pilot drug studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

Plasma exchange in chronic progressive multiple sclerosis: a long-term study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

Controlled pilot trial of monthly intravenous cyclophosphamide in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

Evaluation of myocardial functional parameters during intravenous cyclophosphamide pulse therapy: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

Safety and tolerability of cyclophosphamide 'pulses' in multiple sclerosis: a prospective study in a clinical cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

Preliminary analysis of a trial of pulse cyclophosphamide in IFN-beta-resistant active MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

One-year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

Cyclophosphamide toxicity. Characterising and avoiding the problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

Clinical practice of immunosuppressive treatments in multiple sclerosis: results of a second international questionnaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

Defining the clinical course of multiple sclerosis: Results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

Diagnosis and classification of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

Emerging Treatments in Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

24-month follow-up of multiple sclerosis patients treated with cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

Immunosuppression and plasmapheresis in chronic progressive multiple sclerosis. Design of a clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

7 January 2021

Plasmapheresis With Immunosuppressive Drug Therapy in Progressive Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

7 January 2021

Correlation of clinical and immunologic states in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

7 January 2021

Cyclophosphamide in chronic progressive multiple sclerosis. Maintenance vs nonmaintenance therapy

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

7 January 2021

Cyclophosphamide 'pulses' in chronic progressive multiple sclerosis. A preliminary clinical trial

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

7 January 2021

Effect of intensive immunosuppression on the course of chronic progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

7 January 2021

Effective treatment of chronically progressive multiple sclerosis with low-dose cyclophosphamide with minor side-effects

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

7 January 2021

Short-term intensive cyclophosphamide treatment in progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

7 January 2021

Cyclophosphamide in chronic progressive multiple sclerosis: a comparative study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

7 January 2021

Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

7 January 2021

Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

7 January 2021

Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis: a comparative study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

7 January 2021

Cyclophosphamide in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

7 January 2021

Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

7 January 2021

High-dose cyclophosphamide in multiple sclerosis patients undergoing autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

7 January 2021

Plasmapheresis and combined immunosuppressive drug therapy in chronic progressive multiple sclerosis. Choosing the patient who should respond

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

7 January 2021

Developing clinical outcome measures in multiple sclerosis: an evolving process

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

7 January 2021

Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

7 January 2021

Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

7 January 2021

Acceptance of placebo-control trial design by progressive multiple sclerosis patients. The Canadian Cooperative Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

7 January 2021

Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

7 January 2021

Pulmonary Complications of Combination Therapy with Cyclophosphamide and Prednisone

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

7 January 2021

Immunological monitoring and clinical evaluation in cyclophosphamide-treated progressive multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1002/14651858.CD002819.PUB2

7 January 2021